Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets

In English

Författare

  • J. Capdevila
  • A. Meeker
  • R. Garcia-Carbonero
  • Kristian Pietras
  • A. Astudillo
  • O. Casanovas
  • A. Scarpa

Summary, in English

Neuroendocrine tumors (NETs) represent a heterogeneous group of diseases with varied natural history and prognosis depending upon the organ of origin and grade of aggressiveness. The most widely used biomarker to determine disease burden and monitor response to treatment is chromogranin A (CgA), but it is far from being the optimal predictive and prognostic biomarker in NETs. Biological understanding and derived treatment options for NETs have changed markedly in recent years. Over the last decade, the genomic landscape of these tumors has been extensively investigated. This has resulted in the discovery of mutations and expression anomalies in genes and pathways such as the PI3K/Akt/mTOR, DAXX/ATRX, and MEN1, which are promising predictive and prognostic biomarkers and future candidates for targeted therapies. Additionally, the study of tumor stroma and environment are one of the most promising fields for discovery of potential new targets and biomarkers.

Avdelning/ar

Publiceringsår

2014

Språk

Engelska

Sidor

345-351

Publikation/Tidskrift/Serie

Cancer and Metastasis Reviews

Volym

33

Issue

1

Dokumenttyp

Artikel i tidskrift

Förlag

Springer

Ämne

  • Cancer and Oncology

Nyckelord

  • Neuroendocrine tumors
  • Biomarker
  • Chromogranin A

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 0167-7659